# Mikhail Kosiborod

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mikhail-kosiborod/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,697 |
| Field | Diabetes Treatment and Management |
| h-index | 117 |
| i10-index | 421 |
| Last Known Institution | AstraZeneca (Brazil) |
| OpenAlex ID | https://openalex.org/A5052533254 |
| ORCID iD | 0000-0002-3750-9789 |
| Works | 831 |

## Researcher papers

Showing 12 of 37.

- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association](https://scholariq.org/papers/cardiovascular-kidney-metabolic-health-a-presidential-advisory-from-the-american/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity](https://scholariq.org/papers/semaglutide-in-patients-with-heart-failure-with-preserved-ejection-fraction-and/)
- [A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association](https://scholariq.org/papers/a-synopsis-of-the-evidence-for-the-science-and-clinical-management-of/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/management-of-hyperglycemia-in-hospitalized-patients-in-non-critical-care/)
- [Excess Mortality among Persons with Type 2 Diabetes](https://scholariq.org/papers/excess-mortality-among-persons-with-type-2-diabetes/)
- [SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials](https://scholariq.org/papers/sglt2-inhibitors-in-patients-with-heart-failure-a-comprehensive-meta-analysis-of/)
- [The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial](https://scholariq.org/papers/the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute-heart/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

## Researcher university

- [AstraZeneca (Brazil)](https://scholariq.org/institutions/astrazeneca-brazil/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.